Kraig Biocraft Laboratories (KBLB) EBITDA Margin (2016 - 2018)

Kraig Biocraft Laboratories has disclosed EBITDA Margin across 3 years of filings, most recently posting 105.11% for Q3 2018.

• EBITDA Margin for Q3 2018 came in at 105.11%, up 75604.0% year-over-year; the trailing twelve-month figure through Jun 2019 was 943.24% (down 108224.0% YoY), and the FY2021 annual result was 6898905.0%, changed N/A from the prior year.
• EBITDA Margin came in at 105.11% for Q3 2018 at Kraig Biocraft Laboratories, down from 100.46% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 1586.05% in Q4 2017 to a low of 6657.79% in Q4 2016.
• The 3-year median for EBITDA Margin is 208.56% (2018), against an average of 1739.95%.
• Across the five-year window, EBITDA Margin soared 824384 bps in 2017 and jumped 75604 bps in 2018, its largest moves.
• Kraig Biocraft Laboratories' EBITDA Margin stood at 6657.79% in 2016, then surged by 124 bps to 1586.05% in 2017, then sank by 107 bps to 105.11% in 2018.
• The last three EBITDA Margin figures came in at 105.11% (Q3 2018), 100.46% (Q2 2018), and 208.56% (Q1 2018), per Business Quant data.